Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validation. Genomics. 2003;81:609–17.
Article CAS PubMed Google Scholar
Jin C, Ding P, Wang Y, Ma D. Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett. 2005;579:6375–82.
Article CAS PubMed Google Scholar
Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101–5.
Article CAS PubMed PubMed Central Google Scholar
Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549:106–10.
Article CAS PubMed PubMed Central Google Scholar
Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 2018;35:233–43.
Article PubMed PubMed Central Google Scholar
Chen L, Yang QC, Li YC, Yang LL, Liu JF, Li H, et al. Targeting CMTM6 suppresses stem cell-like properties and enhances antitumor immunity in head and neck squamous cell carcinoma. Cancer Immunol Res. 2020;8:179–91.
Article CAS PubMed Google Scholar
Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology. 2020;10:1864909.
Article PubMed PubMed Central Google Scholar
Wu X, Lan X, Hu W, Zhang W, Lai X, Xu S, et al. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. Cancer Immunol Immunother. 2021;70:3235–48.
Article CAS PubMed PubMed Central Google Scholar
Li X, Chen L, Gu C, Sun Q, Li J. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ. 2020;8:e9536.
Article PubMed PubMed Central Google Scholar
Zhao Y, Zhang M, Pu H, Guo S, Zhang S, Wang Y. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment. Front Oncol. 2020;10:585961.
Zheng Y, Wang C, Song A, Jiang F, Zhou J, Li G, et al. CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1. Am J Cancer Res. 2020;10:1691–709.
CAS PubMed PubMed Central Google Scholar
Wang H, Fan Y, Chen W, Lv Z, Wu S, Xuan Y, et al. Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity. Oncoimmunology. 2022;11:2011673.
Article PubMed PubMed Central Google Scholar
Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik SR, et al. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3beta axis. JCI Insight. 2021;6:e143643.
PubMed PubMed Central Google Scholar
Pang X, Wang SS, Zhang M, Jiang J, Fan HY, Wu JS, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol Immunother. 2021;70:1015–29.
Article CAS PubMed Google Scholar
Huang Y, Zhu Y, Yang J, Pan Q, Zhao J, Song M, et al. CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma. Cell Death Dis. 2022;13:251.
Article CAS PubMed PubMed Central Google Scholar
Wang Z, Peng Z, Liu Q, Guo Z, Menatola M, Su J, et al. Co-expression with membrane CMTM6/4 on tumor epithelium enhances the prediction value of PD-L1 on Anti-PD-1/L1 therapeutic efficacy in gastric adenocarcinoma. Cancers (Basel). 2021;13:5175.
Article CAS PubMed Google Scholar
Althoff T, Mills DJ, Popot JL, Kühlbrandt W. Arrangement of electron transport chain components in bovine mitochondrial supercomplex I1III2IV1. EMBO J. 2011;30:4652–64.
Article CAS PubMed PubMed Central Google Scholar
Kevany BM, Tsybovsky Y, Campuzano ID, Schnier PD, Engel A, Palczewski K. Structural and functional analysis of the native peripherin-ROM1 complex isolated from photoreceptor cells. J Biol Chem. 2013;288:36272–84.
Article CAS PubMed PubMed Central Google Scholar
Tsybovsky Y, Orban T, Molday RS, Taylor D, Palczewski K. Molecular organization and ATP-induced conformational changes of ABCA4, the photoreceptor-specific ABC transporter. Structure. 2013;21:854–60.
Article CAS PubMed PubMed Central Google Scholar
Yang EY, Shah K. Nanobodies: Next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182.
Article CAS PubMed PubMed Central Google Scholar
Ahuja S, Rougé L, Swem DL, Sudhamsu J, Wu P, Russell SJ, et al. Structural analysis of bacterial ABC transporter inhibition by an antibody fragment. Structure. 2015;23:713–23.
Article CAS PubMed Google Scholar
Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008;111:3635–43.
Article CAS PubMed PubMed Central Google Scholar
Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018;10:eaan5488.
Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, et al. ImmuCellAI: A unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci (Weinh). 2020;7:1902880.
Article CAS PubMed Google Scholar
Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112:E6506–E6514.
Article CAS PubMed PubMed Central Google Scholar
Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem. 2013;288:11771–85.
Article CAS PubMed PubMed Central Google Scholar
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.
Article CAS PubMed PubMed Central Google Scholar
Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17–35.
Article CAS PubMed Google Scholar
Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359–70.
Article CAS PubMed PubMed Central Google Scholar
Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15:42–50.
Article CAS PubMed Google Scholar
Ren Y, Qian Y, Ai L, Xie Y, Gao Y, Zhuang Z, et al. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity. Nat Commun. 2021;12:5405.
Article CAS PubMed PubMed Central Google Scholar
Chen Y, Liu P, Gao F, Cheng H, Qi J, Gao GF. A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell. 2010;1:153–60.
Article CAS PubMed PubMed Central Google Scholar
Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 2017;25:1163–74.
Article CAS PubMed Google Scholar
Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7:30323–35.
Article PubMed PubMed Central Google Scholar
Guo Y, Jin Y, Wang B, Liu B. Molecular mechanism of small-molecule inhibitors in blocking the PD-1/PD-L1 pathway through PD-L1 dimerization. Int J Mol Sci. 2021;22:4766.
留言 (0)